Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID-19 'war games': the computer program that could help save your job

11/11/2020 | 09:19am EST
FILE PHOTO: A woman uses a computer keyboard in this photo illustration

LONDON (Reuters) - Bank of England Chief Economist Andy Haldane has signed up to judge the winner of a 'war game' designed to help firms find alternatives to mass layoffs in the face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory, cost-conscious firms have already axed millions of staff worldwide, while UK redundancies hit a record high of 314,000 in the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the COVID-19 War Game to allow executives to explore the impact of huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to alleviate these strains while preserving jobs, in a way that helps both businesses when making difficult commercial decisions and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year and available free to play on the uFlexReward website, calls on players to devise a strategy to cut people costs of a fictional firm by 20%.

Participants weigh up the pros and cons of large-scale redundancies versus alternatives, for the long-term benefit of the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share awards into one real-time cost-base, helping players see different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a so-called 'broad-front' approach, rather than one large saving in more focused cuts like scrapping entire business units or the staff bonus pool.

Financial firms have historically slashed highly paid workforces on the eve of recession, only to rehire rapidly when the economy rebounds.

Swapping this convention for a broad-front approach could minimise the risks that employers end up understaffed and under-skilled when the recovery kicks off, uFlexReward Chief Executive Ken Charman said.


Employers in multiple sectors are facing the prospect of a broader revolution in the world of work, triggered by technology and mass remote working.

"We are still stuck in a very Victorian view of what work is - with fixed working days, for a single employer and in a typically narrow role," Charman said.

"But change is coming that will allow people to be several things at once ... if companies lose people who are highly trained, experienced and loyal, they won't get them back," he said.

Charman hopes the game might persuade employers to waive or cut dividends as well as executive pay increases, and offer job-sharing, reduced hours or part-time roles with flexibility to work elsewhere to staff who might otherwise end up unemployed.

Pushing through alternatives to mass layoffs will require strong leadership and communication, particularly when thousands of employee contracts need to be renegotiated, but retaining staff could leave firms better placed when the recovery begins, Charman said.

"Executives need to be willing to abandon the old conventions; there will be resistance and they've got to be able to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are part of our critical national infrastructure as much as the National Grid. They are the engines of our growth, but they are under threat."

Judging of the head-to-head version of the game, featuring teams made up of executives from Unilever and NYSE-listed technology services provider Endava, will take place on Dec. 3.

Together with Haldane, AstraZeneca senior vice president of reward and inclusion Rebekah Martin, Unilever head of global reward Constantina Tribou, and author David Goodhart are among those judging the strategies.

(Reporting by Sinead Cruise; Editing by Jan Harvey)

By Sinead Cruise

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
ENDAVA PLC -0.25% 79.98 Delayed Quote.4.21%
J SAINSBURY PLC 0.45% 246 Delayed Quote.9.09%
LLOYDS BANKING GROUP PLC -1.54% 34.77 Delayed Quote.-4.58%
NATIONAL GRID PLC 0.81% 875.8 Delayed Quote.1.25%
PROS HOLDINGS, INC. 1.19% 44.31 Delayed Quote.-12.72%
UNILEVER N.V. -0.08% 49.145 End-of-day quote.-0.85%
All news about ASTRAZENECA PLC
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
12:49pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
11:38aItaly PM says vaccine supply delays are serious contract violations
06:06aTHE LATEST : N.Y. seniors, churches to get vaccine prep kits
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
01/22THE LATEST : Online vaccine appointments filling up in Kansas
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159